InvestorsHub Logo
Followers 138
Posts 23416
Boards Moderated 0
Alias Born 04/08/2004

Re: ExtremelyBullishZig post# 398903

Wednesday, 01/18/2023 1:25:26 PM

Wednesday, January 18, 2023 1:25:26 PM

Post# of 465095
The Anavex Alzheimer's disease treatment Phase2b/3 trial was sufficiently powered by design even with 450 participants and the trial was over enrolled with 508 or 509 participants.

The results from the trial are both clinically and statistically significant.

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE

Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL

Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results

GOD bless,
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News